Interleukin-1 Beta-Mediated Sex Differences in Kawasaki Disease Vasculitis Development and Response to Treatment

Rebecca A Porritt1, Janet L Markman1, Daisuke Maruyama1

  • 1From the Division of Infectious Diseases and Immunology, Department of Pediatrics (R.A.P., J.L.M., D.M., B.K., S.C., Y.L., M.N.R., M.A.), Cedars-Sinai Medical Center, Los Angeles, CA.

Insights

Interleukin-1 beta (IL-1β) signaling drives sex differences in Kawasaki disease (KD) vasculitis. While Anakinra treatment improved male mice, it did not benefit female mice, suggesting targeted therapies for KD.

Area of Science:

  • Immunology
  • Pediatric Cardiology
  • Vascular Biology

Background:

  • Kawasaki disease (KD) is a leading cause of acquired heart disease in children.
  • KD affects males more frequently than females.
  • The role of interleukin-1 (IL-1) signaling in KD sex disparities was previously unknown.

Purpose of the Study:

  • To investigate the role of IL-1 signaling in sex-based differences in KD pathogenesis.
  • To determine if IL-1 receptor antagonist Anakinra affects KD vasculitis differently in male and female mice.

Main Methods:

  • Utilized a Lactobacillus casei cell wall extract-induced mouse model of KD vasculitis.
  • Administered PBS, Lactobacillus casei cell wall extract, or extract plus Anakinra to male and female mice.
  • Assessed aortitis, coronary arteritis, and aortic aneurysm formation; performed mRNA-seq and analyzed human KD transcriptomics data.

Main Results:

  • Male mice exhibited more severe aortitis, coronary arteritis, and aortic aneurysms compared to females.
  • Enhanced Il1b and IL-1 signaling gene expression was observed in males.
  • Anakinra treatment ameliorated severe disease in males but did not improve the milder phenotype in females.

Conclusions:

  • IL-1β signaling is a key mediator of sex-based differences in KD vasculitis.
  • The differential response to Anakinra suggests distinct therapeutic strategies may be needed for male and female KD patients.
  • Findings have implications for developing targeted anti-IL-1β therapies for KD.
Abstract